A manufacturer-sponsored secondary analysis found a digital diabetes logbook nearly doubled the odds of reaching HbA1c 6.5% or below at 3 months, with associated real-world glucose reductions. PICO summary and expert commentary.
Browsing: Type 2 Diabetes
Clinical evidence summaries for type 2 diabetes, including glycaemic therapies, cardiovascular outcomes, kidney protection, complications, technology, obesity, and long-term safety.
A small single-blind RCT found that a family-centered empowerment program raised illness acceptance and self-management scores at six weeks in adults with type 2 diabetes. PICO summary and expert commentary.
A Phase 1 crossover study in healthy Korean volunteers found the enavogliflozin/gemigliptin fixed-dose combination pharmacokinetically equivalent to the separate tablets, with food not altering enavogliflozin exposure. PICO summary and expert commentary.
A 52-week open-label randomized trial found once-weekly semaglutide reduced LDL cholesterol and shifted lipoprotein subfractions toward a less atherogenic profile versus sitagliptin in obese type 2 diabetes. PICO summary and expert commentary.
A 12-week randomised trial in older adults with type 2 diabetes testing whether combined aerobic plus resistance exercise improves sleep and abdominal fat. PICO summary and expert commentary.
A 453-patient non-inferiority trial found once-daily prolonged-release pregabalin worked about as well as immediate-release pregabalin for diabetic peripheral neuropathy, with both beating placebo. PICO summary and expert commentary.
A three-arm RCT shows 24 g/day dietary fibre improves HbA1c and the FIB-4 fibrosis marker in type 2 diabetes with MASLD. PICO summary and expert commentary for clinicians.
CARDS demonstrated that atorvastatin 10 mg reduces major cardiovascular events by 37% and stroke by 48% in patients with type 2 diabetes and normal to mildly elevated LDL-cholesterol without prior CVD, confirming that cardiovascular risk rather than LDL level should determine statin initiation and establishing universal statin use in primary cardiovascular prevention for type 2 diabetes.
VADT demonstrated that intensive glucose control achieving a median HbA1c of 6.9% did not significantly reduce cardiovascular events or mortality in veterans with long-standing type 2 diabetes and high cardiovascular disease prevalence, completing the ACCORD/ADVANCE/VADT triptych that defined the limits of aggressive glycaemic management in advanced disease.
ADVANCE demonstrated that intensive glucose control targeting HbA1c below 6.5% using a gliclazide-based strategy reduces nephropathy by 21% and the microvascular composite by 14% in high-risk type 2 diabetes, without the mortality hazard observed in ACCORD, providing important context for how glycaemic targets and treatment strategies interact with safety outcomes.